FOSL1 and neoplasm: The increasingly large arsenal of therapeutic weapons, from tumor-specific nanoparticles to proteasome-targeting chimeras, along with Fra-1-based suicide gene therapies, indicates that the time has definitely come, to unlock the Fra-1 “therapeutic applications’ door” [8].